From the Research
Patients with osteoporosis can generally take Wegovy (semaglutide), but should discuss this with their healthcare provider first, as the most recent study from 2024 1 suggests that the effects of GLP-1Ras on skeletal health remain to be determined.
Key Considerations
- Wegovy is primarily used for weight management and doesn't directly worsen bone health, as noted in a 2022 study 2.
- The weight loss achieved with Wegovy might reduce mechanical stress on bones, which could be beneficial for some osteoporosis patients.
- However, rapid weight loss can sometimes contribute to bone density loss, so bone density monitoring may be recommended during treatment, as suggested by a 2024 study 1.
- Patients should ensure adequate calcium (1000-1200mg daily) and vitamin D (800-1000 IU daily) intake while on Wegovy, as these nutrients are essential for bone health.
- Some gastrointestinal side effects of Wegovy might affect nutrient absorption, so a well-balanced diet rich in bone-supporting nutrients is important.
- Patients should continue any prescribed osteoporosis medications alongside Wegovy, as recommended by a 2019 study 3.
Benefits and Risks
- The benefits of weight management with Wegovy, particularly for overweight patients with osteoporosis, may outweigh potential concerns when properly monitored, as suggested by a 2022 cost-effectiveness analysis 4.
- However, further studies are needed to investigate the bone impact of GLP-1Ra, as noted in a 2024 study 1.
- A 2025 study 5 on the diagnostic utility of one-third radius bone mineral density measurement highlights the importance of accurate bone health assessment in patients with osteoporosis.